作者
Kenneth Lundstrom, Altijana Hromić-Jahjefendić, Esma Bilajac, Alaa AA Aljabali, Katarina Baralić, Nagwa A Sabri, Eslam M Shehata, Mohamed Raslan, Sara A Raslan, Ana Cláudia BH Ferreira, Lidiane Orlandi, Ángel Serrano-Aroca, Vladimir N Uversky, Sk Sarif Hassan, Elrashdy M Redwan, Vasco Azevedo, Khalid J Alzahrani, Khalaf F Alsharif, Ibrahim F Halawani, Fuad M Alzahrani, Murtaza M Tambuwala, Debmalya Barh
发表日期
2023/3/1
来源
Cellular signalling
卷号
103
页码范围
110559
出版商
Pergamon
简介
The COVID-19 pandemic has triggered intensive research and development of drugs and vaccines against SARS-CoV-2 during the last two years. The major success was especially observed with development of vaccines based on viral vectors, nucleic acids and whole viral particles, which have received emergent authorization leading to global mass vaccinations. Although the vaccine programs have made a big impact on COVID-19 spread and severity, emerging novel variants have raised serious concerns about vaccine efficacy. Due to the urgent demand, drug development had originally to rely on repurposing of antiviral drugs developed against other infectious diseases. For both drug and vaccine development the focus has been mainly on SARS-CoV-2 surface proteins and host cell receptors involved in viral attachment and entry. In this review, we expand the spectrum of SARS-CoV-2 targets by …
学术搜索中的文章
K Lundstrom, A Hromić-Jahjefendić, E Bilajac… - Cellular signalling, 2023